FGF1 and soft tissue sarcoma: In the hereby proposed case, the patient was confirmed to have stable disease after two cycles of postoperative chemotherapy (VDC-IE: vincristine, doxorubicin, and cyclophosphamide, alternating with ifosfamide and etoposide), and radiotherapy was therefore performed, followed by anti-angiogenic therapy (anlotinib, a novel oral receptor tyrosine kinase inhibitor targeting vascular endothelial growth factor receptors 2 and 3, fibroblast growth factors 1–4, platelet-derived growth factor receptor α and β, c-Kit, and Ret, applicable to the treatment of soft-tissue sarcoma in China (25, 26)).